These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31720601)

  • 1. The hydrophobically-tagged MDM2-p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a.
    Nietzold F; Rubner S; Berg T
    Chem Commun (Camb); 2019 Nov; 55(95):14351-14354. PubMed ID: 31720601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
    Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
    Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant.
    Anil B; Riedinger C; Endicott JA; Noble ME
    Acta Crystallogr D Biol Crystallogr; 2013 Aug; 69(Pt 8):1358-66. PubMed ID: 23897459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.
    Duan L; Perez RE; Chen L; Blatter LA; Maki CG
    J Mol Cell Biol; 2018 Aug; 10(4):331-340. PubMed ID: 29190376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN; Jiang H; Chang H
    Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-channel surface plasmon resonance monitoring of intracellular levels of the p53-MDM2 complex and caspase-3 induced by MDM2 antagonist Nutlin-3.
    Wu L; Hu Y; He Y; Xia Y; Lu H; Cao Z; Yi X; Wang J
    Analyst; 2019 Jul; 144(13):3959-3966. PubMed ID: 31134974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner.
    Shuvalov O; Kizenko A; Shakirova A; Fedorova O; Petukhov A; Aksenov N; Vasileva E; Daks A; Barlev N
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1233-1239. PubMed ID: 29175211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
    Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
    Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
    Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
    J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.
    Villalonga-Planells R; Coll-Mulet L; Martínez-Soler F; Castaño E; Acebes JJ; Giménez-Bonafé P; Gil J; Tortosa A
    PLoS One; 2011 Apr; 6(4):e18588. PubMed ID: 21483692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.
    Duan L; Perez RE; Lai X; Chen L; Maki CG
    J Biol Chem; 2019 Jun; 294(23):9186-9197. PubMed ID: 31036564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
    Müller CR; Paulsen EB; Noordhuis P; Pedeutour F; Saeter G; Myklebost O
    Int J Cancer; 2007 Jul; 121(1):199-205. PubMed ID: 17354236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
    Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
    Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.
    Trino S; Iacobucci I; Erriquez D; Laurenzana I; De Luca L; Ferrari A; Ghelli Luserna Di Rorà A; Papayannidis C; Derenzini E; Simonetti G; Lonetti A; Venturi C; Cattina F; Ottaviani E; Abbenante MC; Russo D; Perini G; Musto P; Martinelli G
    Oncotarget; 2016 Mar; 7(11):12951-61. PubMed ID: 26887044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On p53 revival using system oriented drug dosage design.
    Haseeb M; Azam S; Bhatti AI; Azam R; Ullah M; Fazal S
    J Theor Biol; 2017 Feb; 415():53-57. PubMed ID: 27979498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
    Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
    Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
    Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
    PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.